Contrave
Designed to target appetite regulation, this product is utilized to support weight control and alleviate behaviours associated with overeating.
- Categories
- Weight Management · Addiction Recovery
- Active ingredients
- Bupropion · Naltrexone
- Supply
- Rx
- Route
- Oral use
- Form
- Prolonged-release tablet
- Strengths
- 8/90mg
Contrave details
- Condition
- Obesity
- Alternative names
- Mysimba
- Therapeutic class
- Weight Loss Agent
- Pharmacological class
- Antiobesity Agent
- Precautions and warnings
- monitor blood pressure
- Minor side effects
- nausea; constipation; headache
- Moderate side effects
- dizziness; insomnia
- Serious side effects
- seizure, requires immediate medical attention
- Dosage forms
- Prolonged-release tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Orexigen Therapeutics
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store at room temperature.
- Drug interactions
- opioids; alcohol
- Age restrictions
- For adults only.
- Pregnancy and breastfeeding
- Pregnancy: Do not use. Breastfeeding: Do not use.
Contraindications
hypersensitivity to components; uncontrolled hypertension; seizure disorders; eating disorders
Patient summary
Designed to target appetite regulation, this product is utilized to support weight control and alleviate behaviours associated with overeating.
Mechanism of action
This combination medication acts by modulating the reward system and appetite-regulating centres in the brain to reduce food cravings and control caloric intake.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Contrave
Contrave combines the active ingredients bupropion and naltrexone, a known pharmaceutical option for the management of obesity. Often sold under the brand name Mysimba, this medication is available as a tablet in a strength of 8/90mg. The manufacturer, Orexigen Therapeutics, developed this dual-action formulation to assist patients with weight control alongside a managed diet and physical activity programme.
Contrave availability in Asia
Contrave is registered across 11 markets including Thailand, Malaysia and the Philippines, with availability also in Taiwan, South Korea and the UAE. Generic variants of similar active ingredients, often manufactured in India, can offer a more budget friendly alternative to the original brand for expats living in regions with limited local stock. As with any treatment for obesity, this product is best used under a doctor’s care.